Phase 2 N=31 Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer
Breast Cancer · Metastatic Breast Cancer
Primary: Time-to-Progression (TTP) — 8.9 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=323 Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Weighted Mean FEV1 Over 0 to 6 Hours Post-dose at Day 42 — -9.90; 181.20; 221.68; 251.87 Milliliters (mL)
Phase 2 N=44 Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease
Cough · Parkinson's Disease
Primary: Peak Expiratory Flow Rate — 4.34; 3.92 Liters of air/second
Phase 2 N=60 Clinical Trial Nuedexta in Subjects With ALS
Amyotrophic Lateral Sclerosis (ALS)
Primary: Bulbar Function Scale (CNS-BFS) Total Score — 53.45; 59.31 units on a scale — p=0.0003
Phase 2 N=156 Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
Other Benign Neoplasm of Skin, Unspecified
Primary: Changes in Putrescine Over 3 Months — 0.03; 1.45; 0.2 nmol/g skin
Phase 2 N=9 Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome
HIV Lipodystrophy
Primary: Insulin Resistance (HOMA Index) — 1.6; 1.8 units on a scale
Phase 2 N=29 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Cervical Cancer · Oropharyngeal Cancer · Vaginal Cancer
Primary: Number of Participants With an Objective Clinical Response — 3; 2; 2; 0 Participants
Phase 2 N=659 A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Percentage of Participants Achieving Objective Response (ORR) Per Response Evaluation Criteria In Solid Tumors (RECIST) Version (v) 1.1 as Assessed by Independent Review…
Phase 2 N=32 Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder
Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency · Carnitine Palmitoyltransferase 2 (CPT2) Deficiency · Mitochondrial Trifunctional Protein (TFP) Deficiency
Primary: Energy Expenditure — -73; 107 kcal/day
Phase 2 N=31 Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches
Delayed Alcohol Induced Headache
Primary: Headache Severity 2 Hours Post Treatment — 2.18; 2.09; 0.85; 1.17 units on a scale
Phase 2 N=10 Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome
Churg Strauss Syndrome
Primary: Number of Participants With Indicated Side Effects — 3; 1; 0; 1 Participants
Phase 2 N=190 Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation
Constipation · Chronic Constipation
Primary: Change From Baseline in Frequency of Spontaneous Bowel Movements — 2.5; 4.0; 5.4; 1.7 Number of SBMs — p=<0.2
Phase 2 N=30 Safety and Efficacy Study of IV Artesunate to Treat Malaria
Malaria
Primary: Change in Percentage of Parasites Detected at 48 Hours — 99.998 percentage of parasite change
Phase 2 N=19 Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease
Aspirin Exacerbated Respiratory Disease (AERD)
Primary: Proportion of Patients Who Experience a ≥ 20% Decrease in Forced Expiratory Volume in One Second (FEV1) Compared to Baseline Following a Dose of Investigational…
Phase 2 N=23 Caffeine and Cocaine
Cocaine Dependence
Primary: Visual Analog Scale Subjective Rating of Drug Effects — 8.65; 9.85; 13.65; 10.43 units on a scale